Search Results

1. onlinelibrary.wiley.com › doi › fullThird‐line antiretroviral therapy, including raltegravir (RAL ...

   onlinelibrary.wiley.com › doi › full

   Jun 15, 2022 · Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

2. www.flightaware.com › live › flightAA5288 (AAL5288) American Airlines Flight Tracking and ...

   www.flightaware.com › live › flight

   • Cached

   Sep 11, 2023 · CLT Charlotte, NC. left Gate 2 Asheville Rgnl - AVL. arrived at Gate E13 Charlotte/Douglas Intl - CLT. Monday 11-Sep-2023 07:33PM EDT. (7 minutes early) Monday 11-Sep-2023 08:54PM EDT. (on time) 1h 21m total travel time. Not your flight? AAL5288 flight schedule. Set Up Unlimited Flight Alerts & More.

3. www.thelancet.com › journals › lanhivThird-line antiretroviral therapy in low-income and middle ...

   www.thelancet.com › journals › lanhiv

   Jul 29, 2019 · We have proposed an algorithmic approach in A5288, which could serve as a compromise between individualised regimens and availability of only one or two third-line regimens. As treatment access has expanded, so has the number of people who might be appropriate for third-line ART.

   • Author: Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Linda...

   • Publish Year: 2019

4. pubmed.ncbi.nlm.nih.gov › 31371262Third-line antiretroviral therapy in low-income and middle ...

   pubmed.ncbi.nlm.nih.gov › 31371262

   Methods: A5288 was a phase 4, third-line ART strategy study done at 19 urban sites in ten countries that enrolled adult participants with confirmed plasma HIV-1 RNA (viral load) of 1000 copies per mL or more after more than 24 weeks of protease inhibitor-based second-line ART. The primary objective was to use antiretrovirals (raltegravir ...

   • Author: Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Linda...

   • Publish Year: 2019

5. Videos

   • 

     10:06

     youtube.com

     Samsung Galaxy A52s 5G SM-A528 Disassembly Teardown Repair

     Apr 6, 2022

     7.6K Views

   • 

     0:56

     youtube.com

     LOTE 176 GPO A5288

     Jul 21, 2023

   • 

     1:17

     youtube.com

     PT588AB Overview Video

     Mar 10, 2017

     6.1K Views

   View all

6. hopkinscidi.org › content › a5288-multioctaveA5288: MULTIOCTAVE, Management Using the Latest Technologies ...

   hopkinscidi.org › content › a5288-multioctave

   • Cached

   Jul 16, 2012 · A5288 is a multi-step, open-label phase IV, prospective, interventional strategy study in resource-limited settings (RLS) for HIV-infected participants with triple-class experience or resistance (ie, to nucleoside reverse transcriptase inhibitors [NRTIs], non-NRTIs [NNRTIs], and protease inhibitors [PIs]) who are failing their current second ...

7. pubmed.ncbi.nlm.nih.gov › 36039892Third-line antiretroviral therapy, including raltegravir (RAL ...

   pubmed.ncbi.nlm.nih.gov › 36039892

   Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 Jun;25 (6):e25905. doi: 10.1002/jia2.25905.

8. Images

   • 
   • 
   • 
   • 

   View all

9. www.researchgate.net › publication › 334754610_ThirdThird-line antiretroviral therapy in low-income and middle ...

   www.researchgate.net › publication › 334754610_Third

   Jul 1, 2019 · Methods: A5288 was a phase 4, third-line ART strategy study done at 19 urban sites in ten countries that enrolled adult participants with confirmed plasma HIV-1 RNA (viral load) of 1000 copies...